iBio Inc. Common Stock (IBIO)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

iBio is not the kind of business I can underwrite on current facts. It is a 23-person preclinical biotech using AI to design antibodies in cardiometabolic and obesity. The commercial record is thin: in fiscal 2026, the year ended 2026-06-30, revenue was $100,000 and net loss $33.0 million; in fiscal 2025 revenue was $400,000 and net loss $18.4 million; fiscal 2024 revenue $225,000 and net loss $24.9 million. The latest filed quarter, fiscal Q1 2026 ended 2025-09-30, had $100,000 revenue and a $5.7 million loss; later quarters showed no revenue and continued losses. That is not a compounding earnings machine; it is a cash-consuming research option. The balance sheet has low debt (D/E 0.03), which helps, but trailing free cash flow was -$23.8 million, a -52.1% FCF yield on a $45.7 million market cap. FairStock's Piotroski score is 2/9 and Altman Z-score -2.31, both warning signs. FairStock's P/B of 0.46 and P/E of -2.22 at the $0.71 close on 2026-10-26 are accounting artifacts of losses, not a margin of safety. Competitive moat is unproven: AI antibody platforms may be promising, but there is no revenue base, no profit, and only 23 employees. The Lynch screen finds no category because losses occurred in each of the last four years. Growth is all future promises, and I cannot value promises. Price at $0.71 may look low versus the 52-week range of $0.69-$3.82, but low price is not value. Without profits or positive cash flow, this is speculation, not investment.

In plain English: iBio is a small, early-stage biotech company that uses artificial intelligence to work on antibody treatments for heart, metabolic, and obesity-related diseases. It has barely any revenue and is losing money: in fiscal 2026 it reported $100,000 of revenue and a $33.0 million net loss. The business looks weak on today's numbers, and the share price is hard to call cheap or expensive because there are no profits to measure it against.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer